



COVID-19 Vaccine Provider Town Hall

8-4-2021



Recorded Town Hall Sessions and Slides Available DHEC's COVID-19 Provider [Website](#)

Webinars

- VIDEO - COVID-19 Vaccine Provider Town Hall Q&A 05.05.21
 - COVID-19 Provider Town Hall 05.05.21 (PDF)

[View Archived Vaccine Provider Webinar](#)



VAMS and DHEC COVID-19 Vaccination Program Updates and Reminders

COVID-19 Vaccination Program Reporting Reminders						
Requirement Area	System	Metrics				Frequency
Inventory	VAMS	New vaccine deliveries	Doses Administered	Waste	Transfers	Same Day
	VaccineFinder	On-hand inventory				Daily
	DHEC Provider Portal H3707	No longer a reporting requirement as of Friday, July 2, 2021				
	VAMS	Inventory Request with 1 st and 2 nd dose amounts specified in notes				Mondays by 11:59pm
Vaccine Administration	VAMS, or Electronic Medical Record/Electronic Health Record with established interface with SIMON, or Direct data entry into SIMON	Vaccine administration event				Within 24 hours
Temperature Monitoring	Via email to COVIDVaccines@dhec.sc.gov Facility Name in the subject line	Temperature monitoring logs for any COVID-19 vaccine containing storage units	Downloaded continuous temperature monitoring device reports		COVID-19 Transport Logs	Fridays by 5pm

VAMS 5.2 (July 28, 2021)

- **Recipient Portal Updates**
- VAMS will send an automatic message to recipients that are due to complete their vaccination protocol (second dose appointment)
- Recipients can schedule multiple dose appointments
- **Clinic Portal Updates**
- Clinic administrators can edit and remove users directly from the Manage Users window on the Clinic setup tab
- Clinic administrators can enable and disable multiple dose appointment reservations
- Front desk users can reserve multiple appointments for recipients, creating simultaneously active first and second dose appointments

Please continue to review the VAMS updates when logging into your VAMS account. These announcements contain the most updated information regarding the system.

VAMS Clinic Work Group

- **Tuesday, August 31, 2021**
- 2:30 PM – 3:30 PM
- Access Link: <https://deloitte.zoom.us/j/93056278831?pwd=NEtGMnJxV1F6ZVFpcXRjdUM0bkl5QT09>
- To join by phone:
- +1 646-518-9805
- Webinar ID: 930 5627 8831
- Passcode: 150419

COVID-19 Provider: DHEC Contacts

- **Provider Operations: COVID-19 Vaccine Management**
 - Vaccine inventory requests, vaccine orders, direct ship vaccine shipments/deliveries, temperature monitoring, transport logs
 - COVIDVaccines@dhec.sc.gov
 - [COVID-19 Vaccine Temperature Excursion Reporting Form and Guidance Document](#)
- **Provider Operations: COVID-19 Provider Support**
 - New enrollment form submissions, vaccine coordinator contact information changes, enrollment form updates, redistribution agreements
 - COVIDProviderEnrollment@dhec.sc.gov
- **DHEC Vaccine Location Web Map**
 - Red/green color updates, information updates
 - VaxStatus@dhec.sc.gov
- **COVID-19 Provider Portal Reporting**
 - Inquiries or assistance with DHEC H3707 Provider Portal
 - Vaxreportinghelp@dhec.sc.gov
- **Provider Operations: New Provider Onboarding and VAMS**
 - Technical assistance, additional clinics, and questions regarding VAMS
 - VAMS@dhec.sc.gov



Please, do NOT submit a SIMON Help Desk Request for any COVID-19 vaccine related issue.

General COVID-19 Vaccination Updates

GBS following Janssen COVID-19 Vaccine

- GBS is a rare autoimmune disorder that causes muscle weakness and paralysis.
- In reviewing the risks and benefits of using the Janssen vaccine, several ACIP members noted that many patients have a strong preference for this single-dose vaccine, and that it is an important and effective option for protection against severe COVID-19 disease, hospitalization, and death. After reviewing the data, **ACIP concluded that the benefits of Janssen COVID-19 Vaccine used according to current recommendations far outweigh the rare potential risks of GBS or thrombosis with thrombocytopenia syndrome (TTS).**

Considerations for Immunocompromised People

- Approximately 2.7% of people in the U.S are immunocompromised due to a health condition or treatment with immunosuppressive medication. These individuals are more likely to become severely ill from infection with SARS-CoV-2 and to transmit the virus to others.
- COVID-19 vaccine effectiveness is lower among immunocompromised individuals, making them more susceptible to breakthrough infection after vaccination.
- An ACIP recommendation would follow FDA authorization of an additional dose. ACIP will continue to assess evidence for the safety, efficacy, and benefit of providing an additional dose of COVID-19 vaccine for immunocompromised people. In the interim, fully vaccinated immunocompromised people should continue to follow the standard recommendations for mask wearing, social distancing, and avoiding large crowds that generally apply to unvaccinated people.

Pfizer 450 Shipper Update

- Pfizer is running short of COVID-19 vaccine shipper boxes and Controlant temperature monitors
 - Smaller Pfizer 450 orders require more shipping containers and monitors than the Pfizer 1170
 - International donations also require shippers and monitors
 - Beginning with orders placed Thursday, 9:30am ET, Pfizer 450 orders of 2 or more to the same location will automatically be combined within the same shipper box
- Jurisdictions and providers may still order Pfizer 450 packages in single shippers by placing individual orders for each Pfizer 450 package
 - This policy will not change the configuration of ancillary kits

Please help by returning your empty shippers and Controlant temperature monitors as soon as possible

Moderna 10 Ordering Discontinued

Effective Wednesday, July 28 at 4pm ET you will no longer be able to order vials of Moderna 10. All supplies in the warehouses have been depleted and no additional Moderna 10 vials will be manufactured. VTrckS ordering for Moderna 10 will be turned off Wednesday at 4pm and only Moderna 14 will be available moving forward.

Potential J&J/Janssen Expiry Extension

- The U.S. Government continues to communicate closely with J&J/Janssen on their vaccine's expiration dates.
- J&J/Janssen has determined that at proper refrigerated storage conditions, the vaccine appears to be very stable across all the lots tested. The company is cautiously optimistic that 6 months total refrigerated storage will be authorized.
- The company has informed us they are hoping to have an extension of the expiration for refrigerated storage of the vaccine to 6 months by early August.
- We ask that you do the following:
 - Continue to use your inventory on hand to prevent wastage of vaccine.
 - Work with approved COVID-19 providers within your jurisdiction and region to transfer doses and optimize vaccine use.
- If the decision regarding the J&J extension is delayed or denied, CDC recommends disposing of expired vials held at provider sites to avoid accidental administration of expired vaccine. If the vaccine is being held at a depot where doses can be appropriately quarantined at the proper temperature, you may continue to store vaccine pending FDA approval of the expiration date extension.

Transporting Vaccine in Vials and Predrawn Syringes

- Ideally, vaccines should be delivered directly to the facility where they will be used. CDC does not recommend routine transport of vaccine vials.
- There may be circumstances where COVID-19 vaccine needs to be redistributed or transported (e.g., satellite, temporary, or off-site clinics, programs at long-term care facilities).
- If vaccines must be transported:
 - Follow the routine vaccine storage and handling transport guidance outlined in CDC's [Vaccine Storage and Handling Toolkit](#). The COVID-19 vaccine addendum includes additional specifics for COVID-19 vaccines, including:
 - • Vaccine must be transported in a stable storage unit and monitored with a DDL.
 - • Use CDC's [transport temperature log](#) to record temperatures and time in transport.
- Transport vaccine in vials whenever possible. Partially used vials may be transported.
- However, there may be limited instances when the only option is to transport vaccine in a provider predrawn syringe. U.S. Pharmacopeia includes guidance for transporting provider predrawn vaccine in syringes in the [USP COVID-19 Vaccine Toolkit: Operational Considerations for Healthcare Practitioners](#).
- Any time spent in transport MUST be included in the beyond-use dates or times for the vaccine products.



Weekly updates will continue to be posted to the COVID-19 Vaccine Provider Guidance [webpage](#).

CONTACT US

Provider Operations Unit

COVID-19 Vaccine Management : COVIDVaccines@dhec.sc.gov

COVID-19 Provider Support : COVIDProviderEnrollment@dhec.sc.gov

VAMS: VAMS@dhec.sc.gov

Stay Connected